187 related articles for article (PubMed ID: 19950289)
1. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.
Su TI; Khanna D; Furst DE; Danovitch G; Burger C; Maranian P; Clements PJ
Arthritis Rheum; 2009 Dec; 60(12):3821-30. PubMed ID: 19950289
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
3. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
4. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Sultan N; Pope JE; Clements PJ;
Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
[TBL] [Abstract][Full Text] [Related]
5. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
Gordon JK; Martyanov V; Magro C; Wildman HF; Wood TA; Huang WT; Crow MK; Whitfield ML; Spiera RF
Arthritis Res Ther; 2015 Aug; 17(1):213. PubMed ID: 26283632
[TBL] [Abstract][Full Text] [Related]
7. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
[TBL] [Abstract][Full Text] [Related]
8. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
9. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.
Quillinan NP; McIntosh D; Vernes J; Haq S; Denton CP
Ann Rheum Dis; 2014 Jan; 73(1):56-61. PubMed ID: 24067785
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.
Karalilova RV; Batalov ZA; Sapundzhieva TL; Matucci-Cerinic M; Batalov AZ
Rheumatol Int; 2021 Oct; 41(10):1743-1753. PubMed ID: 34313812
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.
Allanore Y; Distler O; Jagerschmidt A; Illiano S; Ledein L; Boitier E; Agueusop I; Denton CP; Khanna D
Arthritis Rheumatol; 2018 Oct; 70(10):1634-1643. PubMed ID: 29732731
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
[TBL] [Abstract][Full Text] [Related]
13. Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis.
Ostojic P; Damjanov N
Rheumatol Int; 2011 Aug; 31(8):1051-4. PubMed ID: 20309694
[TBL] [Abstract][Full Text] [Related]
14. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
Mendoza FA; Lee-Ching C; Jimenez SA
Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
[TBL] [Abstract][Full Text] [Related]
16. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
Wannarong T; Muangchan C
Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
[TBL] [Abstract][Full Text] [Related]
17. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
Chakravarty EF; Martyanov V; Fiorentino D; Wood TA; Haddon DJ; Jarrell JA; Utz PJ; Genovese MC; Whitfield ML; Chung L
Arthritis Res Ther; 2015 Jun; 17(1):159. PubMed ID: 26071192
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
[TBL] [Abstract][Full Text] [Related]
19. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
Khanna D; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; de Oliveira Pena J; Yao Z; Kramer F; Distler O
Ann Rheum Dis; 2020 May; 79(5):618-625. PubMed ID: 32299845
[TBL] [Abstract][Full Text] [Related]
20. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
